Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone

International Journal of Nanomedicine
Jinsong LiuYihuai Pan

Abstract

Treatment of cancer metastasized to bone is still a challenge due to hydrophobicity, instability, and lack of target specificity of anticancer drugs. Poly (ethylene glycol)-poly (ε-caprolactone) polymer (PEG-PCL) is an effective, biodegradable, and biocompatible hydrophobic drug carrier, but lacks bone specificity. Polyaspartic acid with eight peptide sequences, that is, (Asp)8, has a strong affinity to bone surface. The aim of this study was to synthesize (Asp)8-PEG-PCL nanoparticles as a bone-specific carrier of hydrophobic drugs to treat cancer metastasized to bone. (1)H nuclear magnetic resonance, Fourier transform infrared spectroscopy, and transmission electron microscopy data showed that (Asp)8-PEG-PCL nanoparticles (size 100 nm) were synthesized successfully. (Asp)8-PEG-PCL nanoparticles did not promote erythrocyte aggregation. Fluorescence microscopy showed clear uptake of Nile red-loaded (Asp)8-PEG-PCL nanoparticles by cancer cells. (Asp)8-PEG-PCL nanoparticles did not show cytotoxic effect on MG63 and human umbilical vein endothelial cells at the concentration of 10-800 μg/mL. (Asp)8-PEG-PCL nanoparticles bound with hydroxyapatite 2-fold more than PEG-PCL. Intravenously injected (Asp)8-PEG-PCL nanoparticles accumulat...Continue Reading

Citations

Sep 10, 2019·Therapeutic Delivery·Vahid Taghipour-SabzevarMehrdad Moosazadeh Moghaddam
Mar 28, 2019·Current Osteoporosis Reports·Miao ZhouJanak L Pathak

❮ Previous
Next ❯

Methods Mentioned

BETA
transmission electron microscopy
enzyme-linked immunosorbent assay
NMR

Software Mentioned

Pro Plus
Image

Related Concepts

Related Papers

Asian Pacific Journal of Cancer Prevention : APJCP
Fatemeh Sadat Tabatabaei MirakabadSang Woo Joo
Asian Pacific Journal of Cancer Prevention : APJCP
Sina MohammadinejadNosratollah Zarghami
© 2022 Meta ULC. All rights reserved